ArticleBMC cancer2022

CpG ODN (K3)-toll-like receptor 9 agonist-induces Th1-type immune response and enhances cytotoxic activity in advanced lung cancer patients: a phase I study.

Tomoyuki Otsuka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.